TCGA-78-7143-01A-11R-2039-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 62
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.470
- MITOTIC_SPINDLE+0.230
- INTERFERON_GAMMA_RESPONSE+0.220
- E2F_TARGETS+0.190
- NOTCH_SIGNALING+0.120
- TGF_BETA_SIGNALING+0.110
- PROTEIN_SECRETION+0.090
- BILE_ACID_METABOLISM+0.070
- HEME_METABOLISM+0.070
- G2M_CHECKPOINT+0.050
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.560
- PANCREAS_BETA_CELLS-0.460
- ANGIOGENESIS-0.430
- MYC_TARGETS_V2-0.380
- OXIDATIVE_PHOSPHORYLATION-0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.370
- HYPOXIA-0.350
- HEDGEHOG_SIGNALING-0.340
- MTORC1_SIGNALING-0.330
- APICAL_JUNCTION-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-A3IV-01A-22R-A21D-07 | — | — | 0.855 |
| 2 | MDT-AP-3269 | Med | Medulloblastoma | 0.792 |
| 3 | TCGA-95-7947-01A-11R-2187-07 | — | cohortA1 | 0.788 |
| 4 | TCGA-D8-A140-01A-11R-A115-07 | — | B | 0.783 |
| 5 | AUR-AF9A-TTP1-A-1-0-R-A741-41 | — | D | 0.777 |
| 6 | 1f1b77a0-a237-47d7-b672-320c327517a3 | — | — | 0.767 |
| 7 | MBCproject_6016_T1_RNA | — | A | 0.765 |
| 8 | SRR4195665 | — | — | 0.762 |
| 9 | TCGA-55-7727-01A-11R-2170-07 | — | cohortMD2 | 0.755 |
| 10 | TCGA-P3-A5QE-01A-11R-A28V-07 | — | — | 0.751 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.220 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.110 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.090 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| G2M_CHECKPOINT | 0.050 | Inavolisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| APOPTOSIS | 0.030 | Idelalisib | — uncovered |